This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frystyk, J. Articles by Baxter, R. C. Search for Related Content PubMed PubMed Citation Articles by Frystyk, J. Articles by Baxter, R. C. Pubmed/NCBI databases Substance via MeSH

Developmental Changes in Serum Levels of Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit in Rats¹

Institute of Experimental Clinical Research, Medical Research Laboratories, Aarhus University Hospital (J.F., H.G., C.S., A.F., H.Ø.), Aarhus, Denmark; and Kolling Institute of Medical Research, Royal North Shore Hospital (J.F., R.C.B.), Sydney, Australia

Address all correspondence and requests for reprints to: Dr. Jan Frystyk, Institute of Experimental Clinical Research, Aarhus Kommune Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. E-mail: jan{at}frystyk.dk

We have recently described a competitive binding assay for rat insulin-like growth factor-binding protein-3 (IGFBP-3) based on the ability of IGFBP-3 to form a ternary complex with the acid-labile subunit (ALS) in the presence of IGF-I. Using this assay we studied groups of male (n = 6) and female rats (n = 6) at 20, 30, 40, 50, 60, 80, and 130 days of age. Nonfasting serum levels of IGFBP-3 were compared with those of total (extractable) IGF-I (tIGF-I) and ALS as well as IGFBP-3 determined by ligand blotting. Additionally, we studied the relationship between ultrafiltered free IGF-I (fIGF-I) and immunoassayable IGFBP-1.

IGFBP-3 was dependent on age only (P < 0.0001), but tended to be higher in males than in females (P = 0.06); between 20–130 days levels increased from 6.5 ± 1.7 to 73.6 ± 7.2 nmol/liter in males and from 5.4 ± 1.6 to 51.3 ± 8.0 nmol/liter in females. IGFBP-3 correlated positively with tIGF-I (r = 0.90; P < 0.0001), ALS (r = 0.92; P < 0.0001), and IGFBP-3, as determined by ligand blotting (r = 0.88; P < 0.0001). The molar ratio of IGFBP-3 to tIGF-I increased from 0.23 ± 0.04 to 0.76 ± 0.04 (P < 0.0001) without any sex dependence. An age- and sex-dependent decrease in IGFBP-1 was observed (P < 0.0001), from 10.9 ± 2.5 to 1.2 ± 0.2 nmol/liter in females and from 8.9 ± 0.7 to 0.2 ± 0.04 nmol/liter in males. Free IGF-I (fIGF-I) increased with age (from 0.7 ± 0.2 to 7.1 ± 0.5 nmol/liter; P < 0.0001), and levels were inversely correlated with IGFBP-1 (r = -0.80; P < 0.0001). In young rats, IGFBP-1 circulated in a 10-fold molar excess over the level of fIGF-I, whereas in older rats, fIGF-I exceeded IGFBP-1 by an average of 9-fold in females and by up to almost 60-fold in males.

We conclude that in rats 1) IGFBP-3 and fIGF-I are strongly age dependent; 2) IGFBP-3 correlates positively with ALS and tIGF-I; and 3) fIGF-I and IGFBP-1 are inversely correlated. This is in accordance with clinical findings. However, in humans the adult level of fIGF-I rarely exceeds 0.3 nmol/liter, and IGFBP-1 usually circulates in excess of fIGF-I. Thus, our results also imply species differences in the IGF systems of humans and rats.

This article has been cited by other articles:

				A. NANDI, Y. KITAMURA, C. R. KAHN, and D. ACCILI Mouse Models of Insulin Resistance Physiol Rev, April 1, 2004; 84(2): 623 - 647. [Abstract] [Full Text] [PDF]

				H. Norrelund, J. Frystyk, J. O. L. Jorgensen, N. Moller, J. S. Christiansen, H. Orskov, and A. Flyvbjerg The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3292 - 3298. [Abstract] [Full Text] [PDF]

				C. A. Shoubridge and L. C. Read Preferential Intestinal Delivery of Long[Arg3] Insulin-Like Growth Factor (LR3IGF-I) over IGF-I in Preweaning and Adult Rats Endocrinology, May 1, 2003; 144(5): 1887 - 1893. [Abstract] [Full Text] [PDF]

				L. E. L. Katz, D. D. DeLeon, H. Zhao, and A. F. Jawad Free and Total Insulin-Like Growth Factor (IGF)-I Levels Decline during Fasting: Relationships with Insulin and IGF-Binding Protein-1 J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2978 - 2983. [Abstract] [Full Text] [PDF]

				N. Miyakoshi, X. Qin, Y. Kasukawa, C. Richman, A. K. Srivastava, D. J. Baylink, and S. Mohan Systemic Administration of Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Increases Bone Formation Parameters in Mice by Increasing IGF Bioavailability via an IGFBP-4 Protease-Dependent Mechanism Endocrinology, June 1, 2001; 142(6): 2641 - 2648. [Abstract] [Full Text] [PDF]

				R. P. Rhoads, P. L. Greenwood, A. W. Bell, and Y. R. Boisclair Organization and Regulation of the Gene Encoding the Sheep Acid-Labile Subunit of the 150-Kilodalton Insulin-Like Growth Factor-Binding Protein Complex Endocrinology, April 1, 2000; 141(4): 1425 - 1433. [Abstract] [Full Text] [PDF]

				J. Frystyk, P. J. D. Delhanty, C. Skjarbak, and R. C. Baxter Changes in the circulating IGF system during short-term fasting and refeeding in rats Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E245 - E252. [Abstract] [Full Text] [PDF]